We aim to genetically identify positive and negative interactors of hyrax to begin to unravel the function of Paf1 complex in the transposon defence in the germline.

While there is no perfect model to simulate all the pathologies associated with human AMD, we use a growing number of approaches to better understand the progression of AMD and retinal degenerations in general. These models also serve to test the efficacy of novel AMD therapeutic and diagnostic pipelines.

Exosomes are paramount to the pathogenesis of a plethora of neurodegenerative diseases but their role in retinal degenerations remains largely unknown. At the Clear Vision Research Lab we study exosomes using several miRNA-centered approaches.

We wish to address gaps in capability by using accurate read-outs of translation efficiency available to us and developing methods for parallel extraction of structural, isoform and RNA-binding protein positional data, together with ligand-specific ribosome localisation read-outs.

Despite only being discovered as recently as the turn of this century, miRNAs are already used in clinical trials as therapeutic candidates for complex diseases. Our research aims to characterise key miRNAs in the retina and exploit those as therapeutic molecules in the retina.

We aim to identify the causative molecular defects to investigate the function of small RNA trimming outside of germline.

We are exploring a number of therapeutic options, developed at ANU and by commercial partners, which include gene-based therapies, non-invasive therapeutics (including the use of low-level laser therapy using red light) and novel compounds.

Major questions about the molecular mechanisms of rapid stress adaptation remain unanswered.

We investigate the neuro-protective benefits of different forms of exercise to retinal health and aim to understand what molecular processes mediate this.Our ongoing projects aim to determine whether or not these benefits can be translated into therapeutic approaches for retinal diseases such as AMD.

We wish to identify malignant-specific rapid responses to drug stress and find new compounds that would block such responses and reduce the adaptation rate.

We aim to molecularly characterise these newly emerging splicing regulations and to investigate their roles in non-germline tissues such as brain and muscles.

We aim to anatomically and molecularly identify the causative defects in the somatic development of piRNA pathway mutant ovaries.